Form 4: Viracta Therapeutics CFO Acquires 500,000 Stock Options

Michael E. Faerm, CFO of Viracta Therapeutics, acquired 500,000 stock options on May 14, 2024, according to a Form 4 filing with the SEC.

Summary

• Michael E. Faerm, the Chief Financial Officer of Viracta Therapeutics, Inc. [VIRX], filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on May 14, 2024.
• Faerm acquired 500,000 stock options (Right to Buy) with an exercise price of $0.804.
• These options vest over time, with 25% vesting on the one-year anniversary of the Vesting Commencement Date (May 13, 2024) and the remaining 1/48th vesting monthly thereafter, contingent upon continued service.
• The options expire on May 14, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to executive compensation. The acquisition of stock options can be seen as a positive sign of confidence, but it's not a major event.

Positives

• The acquisition of stock options by the CFO could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This filing indicates the CFO's acquisition of stock options, which is a common form of executive compensation in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for executives in biotech companies like Viracta Therapeutics.
• Companies such as Amgen, Gilead Sciences, and Biogen also utilize stock options to incentivize their executives.
• The vesting schedule and exercise price are generally aligned with industry norms to motivate long-term performance.

Stakeholder Impact

• The acquisition of stock options by the CFO could have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Form 4, Viracta Therapeutics, Stock Options, Michael E. Faerm, CFO, Beneficial Ownership, VIRX